MI-SCAR-MRI: Characterization of Myocardial Infarction Scar Using Magnetic Resonance Imaging
Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05967026
Collaborator
(none)
150
1
1
147.3
Study Details
Study Description
Brief Summary
The goal of this monocentric observationnal study is to describe the characteristics of the myocardial infarction scar in terms of transmurality in residual LVEF>35% patients.
The primary objective is to determine the frequency of the criterion "intramural scar ≥1.47cm2" (measured by MRI) in patients who presented with myocardial infarction with residual LVEF≥35%.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
150 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Characterization of Myocardial Infarction Scar Using Magnetic Resonance Imaging
Anticipated Study Start Date
:
Jul 1, 2023
Anticipated Primary Completion Date
:
Jul 1, 2023
Anticipated Study Completion Date
:
Aug 1, 2023
Outcome Measures
Primary Outcome Measures
- Intramural scar surface in cm² [6 weeks after myocardial infarction]
Intramural scar surface in cm²>1.47cm²
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Age ≥ 18 years ;
-
History of acute coronary syndrome prior to inclusion and having undergone cardiac MRI;
-
LVEF >35% measured at least 6 weeks post-IDM by echocardiography or MRI;
Exclusion Criteria:
- Patient with an implantable cardiac device (implantable cardioverter defibrillator or pacemaker) prior to MRI.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU of Nancy | Nancy | France | 54000 |
Sponsors and Collaborators
- Central Hospital, Nancy, France
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
HAMMACHE Nefissa,
Residant in Cardiology Unit,
Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT05967026
Other Study ID Numbers:
- 2023PI071
First Posted:
Aug 1, 2023
Last Update Posted:
Aug 1, 2023
Last Verified:
Jul 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by HAMMACHE Nefissa,
Residant in Cardiology Unit,
Central Hospital, Nancy, France
Additional relevant MeSH terms: